Mesoblast (MESO) Stock Price

Mesoblast Price

NYSE·CLOSED
16.78USD-0.14 (-0.83 %)
Market closed

Revenue has compounded at 10.0% per year over the past 19 years to 17.20 M USD. Mesoblast's net margin stands at -593.9%, up from -1,325.3% several years earlier. The stock trades about 30% above its 52-week low.

Mesoblast stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Mesoblast over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Mesoblast stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Mesoblast's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Mesoblast Stock Price History
DateMesoblast Price
8/12/202616.78 USD
8/11/202616.92 USD
8/10/202616.75 USD
8/7/202615.94 USD
8/6/202615.62 USD
8/5/202614.93 USD
8/4/202614.81 USD
8/3/202614.47 USD
7/31/202614.17 USD
7/30/202614.55 USD
7/29/202614.19 USD
7/27/202614.63 USD
7/23/202616.08 USD
7/22/202616.30 USD
7/21/202616.42 USD
7/20/202616.63 USD
7/17/202617.32 USD
7/16/202617.86 USD
7/15/202618.24 USD
7/14/202616.74 USD
7/13/202616.17 USD
7/10/202615.44 USD
7/9/202614.83 USD
7/8/202613.98 USD
7/7/202614.29 USD
7/6/202614.42 USD
7/2/202614.38 USD
7/1/202614.09 USD
6/30/202613.53 USD
6/29/202613.53 USD
6/26/202613.19 USD
6/25/202614.50 USD
6/24/202615.55 USD
6/23/202615.38 USD
6/22/202615.42 USD
6/18/202614.23 USD
6/17/202614.32 USD
6/16/202613.71 USD
6/15/202613.96 USD
6/12/202613.93 USD
6/11/202614.12 USD
6/10/202613.80 USD
6/9/202614.28 USD
6/8/202613.80 USD
6/5/202613.95 USD
6/4/202614.93 USD
6/3/202614.52 USD
6/2/202614.52 USD
6/1/202614.86 USD
5/29/202615.40 USD
5/28/202614.76 USD
5/27/202614.66 USD
5/26/202614.90 USD
5/22/202615.20 USD
5/21/202614.98 USD
5/20/202614.52 USD
5/19/202614.55 USD
5/18/202614.64 USD
5/15/202614.99 USD
5/14/202615.08 USD
5/13/202614.73 USD
5/12/202614.44 USD
5/11/202614.51 USD
5/8/202614.74 USD
5/7/202614.80 USD
5/6/202615.81 USD
5/5/202615.79 USD
5/4/202616.00 USD
5/1/202615.74 USD
4/30/202615.67 USD
4/29/202615.55 USD
4/28/202615.22 USD
4/27/202615.33 USD
4/24/202615.51 USD
4/23/202615.50 USD
4/22/202615.74 USD
4/21/202616.18 USD
4/20/202616.61 USD
4/17/202616.46 USD
4/16/202616.09 USD
4/15/202615.75 USD
4/14/202614.61 USD
4/13/202614.70 USD
4/10/202615.00 USD
4/9/202614.55 USD
4/8/202613.92 USD
4/7/202613.69 USD
4/6/202614.87 USD
4/2/202614.81 USD
4/1/202615.80 USD
3/31/202615.38 USD
3/30/202614.37 USD
3/27/202614.36 USD
3/26/202614.86 USD
3/25/202615.65 USD
3/24/202614.32 USD
3/23/202614.02 USD
3/20/202614.36 USD
3/19/202614.78 USD
3/18/202614.63 USD
3/17/202614.53 USD
3/16/202614.63 USD
3/13/202614.55 USD
3/12/202615.07 USD
3/11/202615.63 USD
3/10/202615.74 USD
3/9/202615.43 USD
3/6/202615.85 USD
3/5/202615.68 USD
3/4/202614.58 USD
3/3/202614.55 USD
3/2/202614.51 USD
2/27/202615.85 USD
2/26/202616.92 USD
2/25/202616.91 USD
2/24/202616.52 USD
2/23/202616.68 USD
2/20/202616.88 USD
2/19/202616.91 USD
2/18/202617.04 USD
2/17/202616.85 USD
2/13/202616.67 USD
2/12/202616.89 USD
2/11/202618.30 USD
2/10/202617.99 USD
2/9/202616.78 USD
2/6/202615.95 USD
2/5/202616.08 USD
2/4/202616.99 USD
2/3/202617.34 USD
2/2/202617.19 USD
1/30/202617.25 USD
1/29/202617.96 USD
1/28/202618.70 USD
1/27/202619.17 USD
1/26/202618.68 USD
1/23/202618.38 USD
1/22/202618.77 USD
1/21/202617.36 USD
1/20/202616.83 USD
1/16/202617.45 USD
1/15/202617.73 USD
1/14/202617.64 USD
1/13/202617.76 USD
1/12/202618.67 USD
1/9/202620.96 USD
1/8/202619.87 USD
1/7/202619.26 USD
1/6/202618.57 USD
1/5/202618.29 USD
1/2/202618.16 USD
12/31/202518.04 USD
12/30/202518.58 USD
12/29/202518.96 USD
12/26/202519.50 USD
12/24/202519.40 USD
12/23/202519.19 USD
12/22/202519.42 USD
12/19/202519.48 USD
12/18/202518.60 USD
12/17/202518.70 USD
12/16/202518.29 USD
12/15/202517.71 USD
12/12/202518.07 USD
12/11/202518.40 USD
12/10/202519.05 USD
12/9/202518.76 USD
12/8/202518.11 USD
12/5/202517.87 USD
12/4/202517.19 USD
12/3/202516.93 USD
12/2/202516.57 USD
12/1/202517.00 USD
11/28/202517.23 USD
11/26/202517.37 USD
11/25/202516.06 USD
11/24/202515.62 USD
11/21/202515.37 USD
11/20/202514.32 USD
11/19/202514.85 USD
11/18/202514.89 USD
11/17/202515.09 USD
11/14/202514.77 USD
11/13/202514.92 USD
11/12/202515.70 USD
11/11/202515.53 USD
11/10/202515.21 USD
11/7/202514.61 USD
11/6/202514.93 USD
11/5/202515.54 USD
11/4/202515.59 USD
11/3/202516.11 USD
10/31/202516.66 USD
10/30/202516.43 USD
10/29/202516.36 USD
10/28/202516.73 USD
10/27/202516.71 USD
10/24/202516.81 USD
10/23/202517.10 USD
10/22/202517.18 USD
10/21/202518.37 USD
10/20/202517.65 USD
10/17/202517.07 USD
10/16/202518.09 USD
10/15/202517.95 USD
10/14/202517.79 USD
10/13/202518.14 USD
10/10/202518.32 USD
10/9/202519.53 USD
10/8/202519.75 USD
10/7/202518.09 USD
10/6/202517.32 USD
10/3/202518.41 USD
10/2/202517.02 USD
10/1/202516.27 USD
9/30/202516.11 USD
9/29/202516.02 USD
9/26/202515.86 USD
9/25/202516.31 USD
9/24/202516.26 USD
9/23/202516.31 USD
9/22/202516.85 USD
9/19/202517.01 USD
9/18/202515.75 USD
9/17/202515.07 USD
9/16/202515.60 USD
9/15/202515.46 USD
9/12/202514.82 USD
9/11/202515.37 USD
9/10/202515.56 USD
9/9/202515.00 USD
9/8/202514.55 USD
9/5/202514.39 USD
9/4/202513.52 USD
9/3/202512.88 USD
9/2/202513.12 USD
8/29/202513.83 USD
8/28/202515.95 USD
8/27/202516.12 USD
8/26/202516.00 USD
8/25/202515.71 USD
8/22/202515.81 USD
8/21/202515.17 USD
8/20/202515.01 USD
8/19/202515.14 USD
8/18/202515.93 USD
8/15/202516.25 USD
8/14/202515.86 USD
Access this data via the Eulerpool API
Get Free API Key

Mesoblast Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
7.50 M USD
-62.81 M USD
-81.89 M USD
Jan 1, 2024
5.90 M USD
-69.31 M USD
-87.96 M USD
Jan 1, 2025
17.20 M USD
-62.44 M USD
-102.14 M USD
Jan 1, 2026 (e)
180.14 M USD
-124.78 M USD
-59.47 M USD
Jan 1, 2027 (e)
311.02 M USD
-200.01 M USD
-7.76 M USD
Jan 1, 2028 (e)
308.96 M USD
-308.96 M USD
98.36 M USD
Jan 1, 2029 (e)
479.00 M USD
-479.00 M USD
160.31 M USD
Jan 1, 2030 (e)
610.00 M USD
-610.00 M USD
236.59 M USD

Mesoblast Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 7:02 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
23.0042.002.0017.0016.0032.007.0010.007.005.0017.00180.00311.00308.00479.00610.00
-8.0082.61-95.24750.00-5.88100.00-78.1342.86-30.00-28.57240.00958.8272.78-0.9655.5227.35
52.1728.57-450.0064.71-362.50-153.13-1,114.29-530.00-671.43-700.0070.5970.5970.5970.5970.5970.59
12.0012.00-9.0011.00-58.00-49.00-78.00-53.00-47.00-35.0012.00127.06219.53217.41338.12430.59
-113.00-81.00-90.00-77.00-87.00-72.00-88.00-80.00-62.00-69.00-62.00-124.00-200.00-308.00-479.00-610.00
-491.30-192.86-4,500.00-452.94-543.75-225.00-1,257.14-800.00-885.71-1,380.00-364.71-68.89-64.31-100.00-100.00-100.00
-119.00-4.00-76.00-35.00-89.00-77.00-98.00-91.00-81.00-87.00-102.00-59.00-7.0098.00160.00236.00
48.75-96.641,800.00-53.95154.29-13.4827.27-7.14-10.997.4117.24-42.16-88.14-1,500.0063.2747.50
53.7753.7747.1449.1853.4458.6464.8177.0585.15114.23129.20129.20129.20129.20129.20129.20
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Mesoblast generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Mesoblast retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Mesoblast's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Mesoblast has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Mesoblast's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Mesoblast stock margins

The Mesoblast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mesoblast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mesoblast.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-1,049.83 %
-1,192.54 %
-1,325.25 %
Jan 1, 2022
-522.58 %
-792.80 %
-894.59 %
Jan 1, 2023
-632.20 %
-837.36 %
-1,091.71 %
Jan 1, 2024
-595.87 %
-1,174.40 %
-1,490.27 %
Jan 1, 2025
70.17 %
-363.08 %
-593.92 %
Jan 1, 2026 (e)
70.17 %
-69.27 %
-33.01 %
Jan 1, 2027 (e)
70.17 %
-64.31 %
-2.49 %
Jan 1, 2028 (e)
70.17 %
-100.00 %
31.84 %

Mesoblast Stock Revenue, EBIT, Earnings per Share

The Mesoblast earnings per share therefore indicates how much revenue Mesoblast has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.12 USD
-1.37 USD
-1.52 USD
Jan 1, 2022
0.13 USD
-1.05 USD
-1.19 USD
Jan 1, 2023
0.09 USD
-0.74 USD
-0.96 USD
Jan 1, 2024
0.05 USD
-0.61 USD
-0.77 USD
Jan 1, 2025
0.13 USD
-0.48 USD
-0.79 USD
Jan 1, 2026 (e)
1.39 USD
-0.97 USD
-0.46 USD
Jan 1, 2027 (e)
2.41 USD
-1.55 USD
-0.06 USD
Jan 1, 2028 (e)
2.39 USD
-2.39 USD
0.76 USD

Mesoblast business model & stock analysis

Mesoblast Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Mesoblast Employees
Details
Date
Mesoblast Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Mesoblast Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Mesoblast historical P/E ratio, EBIT multiple, and P/S ratio

Mesoblast annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Mesoblast shares outstanding

The number of shares of Mesoblast was 129.2 M in 2025. This indicates how many shares Mesoblast is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
64.81 M Stocks
Jan 1, 2022
77.05 M Stocks
Jan 1, 2023
85.15 M Stocks
Jan 1, 2024
114.23 M Stocks
Jan 1, 2025
129.20 M Stocks
Jan 1, 2026 (e)
129.20 M Stocks
Jan 1, 2027 (e)
129.20 M Stocks
Jan 1, 2028 (e)
129.20 M Stocks

Mesoblast stock splits

In Mesoblast's history, there have been no stock splits.
Price targets and forecasts for Mesoblast are not yet available.

Mesoblast Analyst Rating Actions

DateFirmActionRatingReliability
11/25/2025
Jefferies
Jefferies
UpgradeHoldBuy47
7/18/2025
Jefferies
Jefferies
DowngradeBuyHold47
2/7/2025
Piper Sandler
Piper Sandler
MaintainedOverweight51
12/23/2024
Jefferies
Jefferies
DowngradeBuyHold47
12/19/2024
Piper Sandler
Piper Sandler
MaintainedOverweight51
7/23/2024
Piper Sandler
Piper Sandler
UpgradeNeutralOverweight51
9/20/2023
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
8/30/2023
Jefferies
Jefferies
UpgradeHoldBuy47
8/30/2023
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
8/6/2023
Maxim Group
Maxim Group
DowngradeBuyHold–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Mesoblast Earnings Calls

Mesoblast shareholder structure

% Name
0.57115%
JANE STREET GROUP, LLC
JANE STREET GROUP, LLC
0.48797%
BLACKROCK, INC.
BLACKROCK, INC.
0.39791%
MORGAN STANLEY
MORGAN STANLEY
0.32355%
CITADEL ADVISORS LLC
CITADEL ADVISORS LLC
0.30725%
GOLDMAN SACHS GROUP INC
GOLDMAN SACHS GROUP INC
0.29894%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
SUSQUEHANNA INTERNATIONAL GROUP, LLP

Mesoblast Beneficial Ownership Filings (SEC 13D/G)

Free Float
63.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
22.36%
George, Gregory
George, Gregory
SEC ↗
21.59%
Gregory George
Gregory George
SEC ↗
17.95%
in Row (9)
in Row (9)
SEC ↗
17.88%
17.88%(3)
17.88%(3)
SEC ↗
14.65%
Amount in Row (9)
Amount in Row (9)
SEC ↗
11.00%
M&G Investment Management Limited
M&G Investment Management Limited
SEC ↗
11.00%
M&G Investment Funds (3)
M&G Investment Funds (3)
SEC ↗
11.00%
No I.R.S Identification
No I.R.S Identification
SEC ↗
8.50%
Capital World Investors **
Capital World Investors **
SEC ↗
8.24%
M&G Investment Management
M&G Investment Management
SEC ↗

Frequently asked questions about Mesoblast

Converted at the current exchange rate, the Mesoblast share trades at 14.55 EUR (16.78 USD).

No history available for Mesoblast.

The expected revenue of Mesoblast is 180.14 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Mesoblast is -59.47 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mesoblast is currently -36.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mesoblast stock.

The price-to-sales ratio (P/S) of Mesoblast is currently 12.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mesoblast stock.

The Eulerpool Quality Score for Mesoblast is 3/10.

The ISIN of Mesoblast is US5907171046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Mesoblast is A2AA6U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Mesoblast is MESO. The ticker symbol is used to trade Mesoblast shares on the stock exchange.

Mesoblast paid dividends every year for the past 0 years.

Mesoblast is assigned to the 'Health' sector.

The dividends of Mesoblast are distributed in USD.

All fundamentals and in-depth analysis of Mesoblast

Our stock analysis for Mesoblast stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Mesoblast Stock
Mesoblast Revenue→
Mesoblast Stock
Mesoblast Net Income→
Mesoblast Stock
Mesoblast P/E→
Mesoblast Stock
Mesoblast P/S→
Mesoblast Stock
Mesoblast EBIT→
Mesoblast Stock
Mesoblast Dividend→
Mesoblast Stock
Mesoblast Directors Dealings→
Mesoblast Stock
Mesoblast Stocks→
Mesoblast Stock
Mesoblast Market capitalization→
Mesoblast Stock
Mesoblast Debt→
Mesoblast Stock
Mesoblast Liabilities→
Mesoblast Stock
Mesoblast Equity→
Mesoblast Stock
Mesoblast AAQS→
Mesoblast Stock
Mesoblast Employees→
Mesoblast Stock
Mesoblast ROE→
Mesoblast Stock
Mesoblast ROA→
Mesoblast Stock
Mesoblast ROCE→
Mesoblast Stock
Mesoblast News→
Mesoblast Stock
Mesoblast Analyst Price Targets→

Health Stocks

Metabiomed CoMesa LaboratoriesMetacare CoMerit Medical SystemsMetagenomi TherapeuticsMeridian BioscienceMetall ZugMereo BioPharma GroupMetaStatMerdury BiopharmaceuticalMetaViaMerck Tbk PTAll Stocks A–Z →